Agilent, Seoul National University Hospital Announce Strategic Collaboration on Biomarker Research

Agilent Technologies (NYSE: A) and Seoul National University
Hospital, one of Korea's top medical centers, today announced a
strategic collaboration for the development and verification of various
biomarkers for the development of drugs, including narcotics,
immune-suppressants and biomarkers.

“There are gaps in the medical industry that hamper the quality of care
we can provide to patients,” said Prof. Byung-Hee Oh, president and CEO,
Seoul National University Hospital. “One area we want to address is the
development of biomarkers for early detection and effective monitoring
of a range of diseases.”

“Our hospital is pleased to collaborate with Agilent, the premier test
and measurement company,